What Not To Do When An FDA Inspector Comes Knocking At Your Door
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tweaks final guidance on what constitutes interference with FDA inspections to include examples of ‘reasonable’ explanations for sponsor delays; industry had requested many other changes.
You may also be interested in...
US FDA Invites Warning Letter Follow-Up Inspection Alternative Proposals As Pandemic Persists
With inspectorate grounded by COVID-19, agency cannot clear remediated facilities or approve related applications – unless industry has a better idea.
US FDA Guidance On Interference With Inspections Needs More Detail, Attorneys Say
Agency should clarify how quickly it expects requested documents to be produced before a company is determined to have delayed an inspection, attorneys say during a FDLI meeting discussion of how a 2012 law enabling the agency to put a foreign facility on import alert for delaying, limiting, or refusing an inspection has played out.
In Brief: FDA testing, FDA inspection creep, Q11 ‘clarified,’ enforcement dashboard, data integrity, more
FDA posts testing results; regulatory creep knocks at door; ICH Q11 ‘clarified’ for Europe; FDA’s new enforcement dashboard; data integrity insights; FDA’s Arista challenges India; FDA’s new quality platform.